Glomerular hyperfiltration may contribute to the high incidence of renal disease in Obese African Americans essential hypertensive (ObAAEH) patients, but the precise mechanisms responsible for renal injury have not been elucidated. Mitochondria are important determinants of renal injury in hypertension, and increased levels of mitochondrial DNA (mtDNA) in the urine may indicate renal mitochondrial injury. We hypothesized that urine mtDNA copy numbers would be higher in ObAAEH compared to Caucasian essential hypertensive (CEH) patients.
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The prevalence of hypertension in African Americans is among the highest in the world, reaching an alarming 44.9% and 46.1% in men and women, respectively. 1,2 Obese African American essential hypertensive (ObAAEH) patients have an increased risk for developing chronic kidney disease and reach end-stage renal disease earlier than their Caucasian EH (CEH) counterparts. 3 Therefore, there is a pressing need to elucidate the mechanisms implicated in hypertensioninduced renal damage in this ethnic group.
Previous studies indicate that alterations of intrarenal hemodynamics may contribute to the higher incidence of renal injury in ObAAEH. Renal blood flow, glomerular filtration rate (GFR), and urinary albumin levels are elevated in ObAAEH and further increase in response to norepinephrine, suggesting glomerular hyperfiltration. 4 Furthermore, ObAAEH have impaired GFR autoregulation and glomerular hyperfiltration in response to increased dietary sodium intake. 5 In agreement, we have previously shown that GFR is higher in ObAAEH compared to CEH, associated with increased oxidative stress and renal medullary hypoxia. 6 However, the exact molecular mechanisms underlying renal hyperfiltration in ObAAEH remain to be elucidated.
Mitochondria are present in large amounts in renal cells to satisfy the high energy demand of the kidney. 7 These organelles are primarily responsible for ATP production, but also regulate cellular oxidative stress, proliferation, apoptosis, and calcium signaling. 8, 9 Thus, mitochondrial injury may compromise renal cell function. 10 Experimental evidence suggests that mitochondrial damage is implicated in the pathogenesis of hypertension-induced renal injury, 11 but human data are limited partly because it requires a renal biopsy, which is unlikely to be performed in uncomplicated hypertensive patients.
Increased levels of mitochondrial DNA (mtDNA) in the urine has emerged as a noninvasive and clinically useful index of renal mitochondrial dysfunction. Urinary mtDNA is elevated in patients with acute kidney injury and is associated with progression in its severity. 12,13 Likewise, we have recently shown that elevated urinary mtDNA copy numbers in hypertensive patients correlated with markers of renal injury and dysfunction. 14 However, whether disruption of mitochondrial integrity in the context of glomerular hyperfiltration may be associated with detectable release of mtDNA into the urine of ObAAEH has never been explored. Therefore, this study tested the hypothesis that urine mtDNA copy numbers originating in the kidneys would be higher in ObAAEH compared to CEH patients.
METHODS

Patient population
Nondiabetic CEH and ObAAEH patients (n = 23 in each group) from the Mayo Clinic (Rochester, MN), University of Mississippi (Jackson, MS), or University of Alabama (Birmingham, AL) were prospectively enrolled after providing written informed consent and the approval of the Institutional Review Board of the Mayo Clinic. Twenty-three consenting healthy volunteers (HV) served as controls (Mayo Clinic Biobank).
Inclusion criteria for hypertensive patients included blood pressure ≥140/90 mm Hg, previous diagnosis of hypertension, and/or current use of antihypertensive medications.
All CEH and ObAAEH patients participated in this study during a 3-day inpatient protocol in the Clinical Research Unit of St Mary's Hospital, Rochester, MN. Dietary sodium intake was maintained at a constant level (150 mEq/d) for 3 days and patients continued with any prescribed angiotensin converting enzyme inhibitors or angiotensin receptor blockers at usual recommended daily doses. Patients with systolic blood pressure ≥180 mm Hg despite antihypertensive therapy, or serum creatinine ≥2.5 mg/dl, were excluded, as were those with a history of major cardiovascular events within the last 6 months, pregnancy, or kidney transplant.
HV were enrolled by using the following inclusion criteria: blood pressure ≤130/80 mm Hg, no history of hypertension or cardiovascular disease, and not taking antihypertensives, lipid-lowering drugs, or any medication listed in the algorithms from electronic Medical Records and Genomics. 15 
Clinical data collection and laboratory measurements
On day 1, demographics and laboratory data including age, gender, body mass index, systolic, diastolic, and mean arterial pressure were collected. Total cholesterol, low-density lipoprotein, and serum creatinine were measured by standard procedures.
Estimated GFR was calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula. 16 In addition, measured GFR was quantified in all hypertensive patients (ObAAEH and CEH) by iothalamate clearance (iothalamate meglumine; Conray, www.imaging-.mallinckrodt.com). 6, 17 Urine samples were collected for 24-hour total protein levels in CEH and ObAAEH, whereas spot urine samples were obtained from HV. Samples were centrifuged, and the supernatant stored immediately at −80 °C until measurement to prevent catalytic degradation. Urinary protein, urinary sodium, and urinary creatinine levels were measured by standard procedures. Filtered sodium was calculated as the product of serum sodium and measured GFR and expressed as mEq/day. Fractional excretion of sodium was calculated with the following formula: (urinary sodium × plasma creatinine)/(plasma sodium × urinary creatinine) × 100, and total absolute amount of sodium reabsorbed as: (GFR × [plasma sodium]) − (urine flow rate × [urine sodium]).
On day 3, a catheter was placed via the femoral or internal jugular vein of CEH and ObAAEH patients and 120 ml of blood obtained from both the right and left renal veins (RVs) and the inferior vena cava (IVC). 18, 19 In HV, peripheral (antecubital) blood samples were collected.
Plasma and urine mtDNA
Plasma and urinary levels of the mitochondria encoded cytochrome-c oxidase-3 (COX3) and nicotinamide adenine dinucleotide dehydrogenase subunit-1 (ND1) were measured by quantitative real-time PCR, as previously described. 14 In brief, plasma (200 µl) and urine (1.75 ml) mtDNA were isolated using DNA isolation kits from Qiagen, Venlo, Netherlands (Cat# 51104) and Norgen Biotek, Ontario, Canada (Cat# 18100), respectively. Isolated mtDNA was then eluted in the total volume of elution buffer (150 µl), DNA concentrations measured by a Spectrophotometer (NanoDrop), and 7.2 ng/sample added into PCR reactions. Primers and TaqMan copy number assays were purchased from Life Technology (Life Technology, Carlsbad, CA, COX3: forward 5ʹ-AGGCATCACCCCGCTAAATC-3ʹ and reverse 5ʹ-GGTGAGCTCAGGTGATTGATACTC-3ʹ and ND1: forward 5ʹ-AGTCACCCTAGCCATCATTCTACT-3ʹ and reverse 5ʹ-GGAGTAATCAGAGGTGTTCTTGTGT-3ʹ. Absolute COX3 and ND1 copy numbers were calculated using plasmid constructs (Blue Heron BioTechnology, Bothell, WA, NC0129201 and OriGene, Rockville, MD, SC101172, respectively) on Applied Biosystems ViiA7 Real-Time PCR systems. To identify mitochondrial-specific cellular damage, mtDNA copy numbers were corrected to the nuclear control gene RNAse-P (Invitrogen, Cat# 4403326) using a human genomic DNA for the standard curve (Invitrogen, Cat# 360486) and urinary creatinine (Arbor assays, Cat# K002-H1). COX3 and ND1 levels were expressed as copies/µl.
Renal COX3 and ND1 gradients were calculated by subtracting IVC from RV levels assess release of mtDNA specifically from the kidney. 18 We have previously shown that the difference between infrarenal IVC and RV levels reflects the release of injury markers within the kidney. [18] [19] [20] 
Statistical analysis
Statistical analysis was performed with JMP version 10.0 (SAS Institute, Cary, NC). Data distribution was assessed by the Shapiro-Wilk test. Gaussian distributed data was expressed as mean ± SD, and compared using analysis of variance with Tukey's post-hoc, whereas nonnormally distributed data were expressed as medium (interquartile range 25-75%), and compared using Wilcoxon and Kruskal-Wallis nonparametric tests with Steel-Dawss post-hoc. Regressions were calculated by the least-squares fit. Urinary mtDNA levels were log-transformed. Univariate and multivariate models were applied to evaluate ethnicity, age, gender, body mass index, estimated GFR, and urinary protein effects on urinary COX3 and ND1. A P value <0.05 was considered statistically significant. Table 1 shows the clinical, laboratory, and demographic characteristics of the study patients. Body mass index was higher, whereas age was lower and fewer women were recruited in ObAAEH compared with HV and CEH patients. Both systolic blood pressure and mean arterial pressure were similarly higher in CEH and ObAAEH compared to HV, whereas diastolic blood pressure did not differ among the groups. Duration of hypertension and number of antihypertensive drugs and statins were comparable between hypertensive groups. Total cholesterol, low-density lipoprotein, as well as serum and urine creatinine, urine protein, and protein/creatinine ratio were similar among the groups. However, estimated GFR was higher in ObAAEH compared to HV and CEH, and measured GFR higher in ObAAEH compared to CEH. Urinary sodium and FeNa were similar between hypertensive groups (P > 0.05), whereas filtered sodium and total sodium reabsorbed were higher in ObAAEH compared to CEH.
RESULTS
Urinary and plasma mtDNA
Urinary COX3 and ND1 were higher in CEH compared to HV, and further elevated in ObAAEH patients (Figure 1 ), whereas RNAse-P copy number did not differ among the groups (P = NS). Hence, the increase in COX3 and ND1 was specific to mtDNA rather than overall cellular DNA.
Systemic and RV plasma levels of COX3 and ND1 were similar among the groups, but only in CEH patients, levels of COX3 and ND1 were lower in the RV vs. IVC (Figure 2a) . Consequently, the cross-kidney gradients of mtDNA were higher in ObAAEH compared to CEH (Figure 2b ). Statistical differences in urinary COX3 and ND1 copy number between the groups persisted after correction for urinary creatinine (P < 0.0001 and P < 0.001, respectively). Urinary mtDNA levels differed by ethnicity, age, gender, and GFR in univariate comparison, but in multivariate analysis, GFR remained the only predictor of elevated urinary COX3 and ND1 levels (Supplementary Table S1 ).
In ObAAEH (but not in CEH) patients, urinary COX3 and ND1 directly correlated with GFR (Figure 3a) , whereas in CEH GFR did not correlate with either urinary COX3 or ND1 (Figure 3b ). Urinary mtDNA copy number did not correlate with systolic blood pressure, diastolic blood pressure, or mean arterial pressure in either CEH or ObAAEH (all P = NS). Filtered sodium, urinary sodium, and particularly total sodium reabsorbed correlated directly with urinary mtDNA (Figure 4 ), but FeNa did not correlate with either urinary COX3 or ND1 (both P > 0.05).
DISCUSSION
This current study shows that urinary levels of fragments of the mitochondrial genome are elevated in ObAAEH patients and correlate with glomerular hyperfiltration after correction for covariates. Furthermore, in ObAAEH, mtDNA developed a positive gradient across the kidney, implying selective renal release in both the urine and venous blood. These observations suggest that kidneys of ObAAEH subjects may exhibit mitochondria injury, which in turn may potentially aggravate renal damage and accelerate hypertension-related morbidity/mortality rates.
Renal failure appears earlier and progresses faster in ObAAEH compared to CEH, but the mechanisms underlying this racial disparity remain to be elucidated. 21 Genetic susceptibility (variants within the apolipoprotein L1 22 and MYH9 23 genes) and salt sensitivity 24 have been proposed as important contributing factors to support the increased risk of hypertensive renal disease. Furthermore, we have previously shown that RV and circulating inflammatory markers are elevated in ObAAEH patients and correlate with decreased endothelial progenitor cell levels, suggesting that impaired renal reparative capacity may predispose to hypertensive vascular injury. 25, 26 Yet, the contribution of mitochondrial injury to this disparity remained unclear.
Obesity is an important contributor to hypertension in all ethnic groups that causes structural changes in the kidneys and loss of nephron function. 27 Glomerular hyperfiltration is an important obesity-related physiological effect commonly observed in ObAAEH patients. 28 Importantly, this observation resulted in the inclusion of ethnicity as a component of the Modification of Diet in Renal Disease GFR equation. 29 In patients with CEH, high creatinine clearance (suggesting glomerular hyperfiltration) is an important predictor for the development of early hypertensive nephropathy. 30 The current model of "sodium glomerulopathy" also suggests that sodium sensitivity in ObAAEH results from an increased activity of Na-K-2Cl cotransport in the thick ascending limb of Henle's loop, 31 but the mechanisms by which glomerular Figure 3 . Urinary mtDNA copy number correlates with renal hyperfiltration. In ObAAEH patients, urinary COX3 and ND1 copy number correlated directly with mGFR (a), whereas in CEH mGFR did not correlate with either urinary COX3 or ND1 (b). Abbreviations: CEH, Caucasian essential hypertensive; mGFR, measured glomerular filtration rate; mtDNA, mitochondrial DNA; NS, nonsignificant; ObAAEH, Obese African American essential hypertensive.
hyperfiltration induces kidney damage in ObAAEH remain to be determined. The current study highlights a novel potential mechanism by which glomerular hyperfiltration may injure the kidney in ObAAEH. We found that urinary COX3 and ND1 levels were elevated in ObAAEH patients and directly correlated with GFR, suggesting that mitochondrial injury may result from and/or aggravate hypertensionrelated renal damage in ObAAEH.
Previous studies have shown that urinary mtDNA, which may escape from injured cellular mitochondria to the urine or systemic circulation, is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury. 12 In agreement, we have previously shown that urinary mtDNA is elevated in hypertensive patients and correlates with markers of renal injury and dysfunction, suggesting that mitochondria are implicated in renal injury and might represent a novel therapeutic target in hypertension. 14 A previous study has reported mitochondrially encoded gene mutations associated with renal dysfunction in peripheral blood lymphocytes of ObAAEH, suggesting that mtDNA may account for a subgroup of ObAAEH with end-stage renal disease. 32 In order to cover the entire spectrum of the mitochondrial respiratory chain, we measured urinary levels of COX3 and ND1, which encode for subunits of the terminal enzyme of the mitochondrial respiratory chain (complex-III) and the enzyme responsible for the first step in the electron transport (complex-I), respectively. Furthermore, these genes are located in opposite regions of the circular mtDNA. 33 Hence, we ensured adequate functional and anatomical representation of mtDNA. Previous studies have shown that urinary levels of COX3 and ND1 were similarly elevated in patients with AKI, reflecting renal mitochondrial damage. 12, 13 In this study, we found higher urinary mtDNA levels in ObAAEH that correlated directly with GFR, extending previous observations and implicating mitochondrial injury in the consequences of glomerular hyperfiltration in ObAAEH subjects.
Furthermore, we provide evidence demonstrating renal release of mtDNA into the systemic circulation, reflected in a positive gradient across the kidney. We have previously shown that the cross-kidney gradients of inflammatory markers reflect their release within the affected kidney. 18 Importantly, mtDNA has potent proinflammatory properties via Toll-Like Receptor (TLR)-9 mediated responses, which may induce inflammation in remote organs. 34 Indeed, circulating mtDNA levels are elevated in maintenance hemodialysis patients, and closely correlate with chronic inflammation. 35 However, the unchanged circulating levels of COX3 and ND1 among the groups are inconsistent with mtDNA-induced systemic inflammation in our study.
The mechanisms linking mitochondrial injury and glomerular hyperfiltration remain unclear, and are likely multifactorial. Obesity and hypertension, which are commonly associated with mechanical stretch, increased production of reactive oxygen species, extracellular matrix turnover, and fibrosis, may alter the structure and function of the mitochondrion. 11 Furthermore, in the current study, glomerular hyperfiltration in ObAAEH was associated with increased filtered sodium, but urinary sodium levels and FeNa were similar between hypertensive groups. Interestingly, total sodium reabsorbed was higher in ObAAEH compared to CEH, and correlated better with urinary COX3 and ND1 levels than filtered sodium, suggesting that increased sodium reabsorption may contribute to renal mitochondrial injury in ObAAEH. Further experimental and clinical research is needed to explore the precise cause and effect relationships between mitochondrial injury and hyperfiltration in ObAAEH patients.
Speculatively, changes in GFR might be partly due to mitochondrial damage of the cellular components of the glomerular filtration membrane. This highly specialized structure ensures selective ultrafiltration of plasma and is primarily composed by podocytes and endothelial cells. 36 Furthermore, increased glomerular pressure and stretch may lead to cellular injury and mitochondrial fragmentation. Substantial levels of energy are required to maintain podocyte structure and function, which is primarily derived from the respiratory chain of the inner mitochondrial membrane. 37 Therefore, renal mitochondrial injury may result in podocyte damage and loss of barrier function. Likewise, glomerular endothelial cell mitochondrial injury may compromise the integrity of the filtration barrier. 38 Further studies are needed to explore the mechanisms and consequences of hypertension-induced renal mitochondrial injury.
Because of the prospective and well-controlled nature of our study, as well as RV catheterization, our study is limited by its cross-sectional nature and the relatively small number of participants. Patients were not specifically matched by age and gender; age was lower and fewer women were recruited in ObAAEH compared with HV and CEH patients. Nevertheless, none of these parameters remained predictors of elevated urinary mtDNA levels in multivariate analysis. Incidentally, a wide range of GFR values resulted in a spectrum of mtDNA values in our patients. Despite significant correlations between GFR and urinary mtDNA levels, we cannot rule out the possibility that other factors may have contributed to mitochondrial damage in ObAAEH. For example, angiotensin-II receptor activation in the inner mitochondrial membrane may induce mitochondrial dysfunction, 39 but blockade of the reninangiotensin-aldosterone system in the hypertensive groups argue against this mechanism. Whether treatment with antihypertensive drugs may alter urinary COX3 and ND1 levels requires future studies. We have not measured urinary levels of enzymes, which could degrade DNA, but samples were frozen immediately to avoid catalytic degradation.
In summary, this study shows that ObAAEH subjects have increased levels of markers of mitochondrial injury, as measured by urinary COX3 and ND1 copy number. Furthermore, urinary mtDNA levels correlate directly with GFR, suggesting that mitochondria may be implicated in glomerular hyperfiltration. These observations may position mitochondria as novel therapeutic targets to attenuate hypertensionrelated morbidity and mortality rates in ObAAEH.
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